Organism: Homo sapiens
Gene: 39692_at
Selected probe(set): 212345_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39692_at (212345_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.5347385
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):4.1662884
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-4.0910378
Number of Samples:2 / 2

Experimental	zalypsis study 2
	OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control	untreated OPM1 cell sample
	OPM1 multiple myeloma cells untreated.

Relative Expression (log2-ratio):3.8396807
Number of Samples:3 / 3

Experimental	tunicamycin study 2 (2ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):3.4020605
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):3.3380089
Number of Samples:3 / 3

Experimental	tunicamycin study 2 (2ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):3.3055944
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):3.1310463
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal T-cell; 20uM)
	MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):2.746851
Number of Samples:3 / 3

Experimental	tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 DICER1(-/-) cell sample
	Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):2.6676674
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal T-cell sample
	MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.